- Home
- IMAB vs ETON Comparison
IMAB vs ETON Comparison
Compare IMAB & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ETON
- Stock Information
- Founded
- IMAB 2014
- ETON 2017
- Country
- IMAB United States
- ETON United States
- Employees
- IMAB N/A
- ETON N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ETON Health Care
- Exchange
- IMAB Nasdaq
- ETON Nasdaq
- Market Cap
- IMAB 394.2M
- ETON 388.3M
- IPO Year
- IMAB 2020
- ETON 2018
- Fundamental
- Price
- IMAB $4.39
- ETON $21.45
- Analyst Decision
- IMAB Strong Buy
- ETON Strong Buy
- Analyst Count
- IMAB 6
- ETON 3
- Target Price
- IMAB $7.17
- ETON $29.67
- AVG Volume (30 Days)
- IMAB 1.7M
- ETON 343.9K
- Earning Date
- IMAB 11-02-2025
- ETON 11-11-2025
- Dividend Yield
- IMAB N/A
- ETON N/A
- EPS Growth
- IMAB N/A
- ETON N/A
- EPS
- IMAB N/A
- ETON N/A
- Revenue
- IMAB N/A
- ETON $58,181,000.00
- Revenue This Year
- IMAB N/A
- ETON $105.25
- Revenue Next Year
- IMAB N/A
- ETON $40.84
- P/E Ratio
- IMAB N/A
- ETON N/A
- Revenue Growth
- IMAB N/A
- ETON 85.40
- 52 Week Low
- IMAB $0.60
- ETON $6.37
- 52 Week High
- IMAB $5.90
- ETON $23.00
- Technical
- Relative Strength Index (RSI)
- IMAB 59.97
- ETON 66.33
- Support Level
- IMAB $3.98
- ETON $19.48
- Resistance Level
- IMAB $4.51
- ETON $23.00
- Average True Range (ATR)
- IMAB 0.30
- ETON 1.15
- MACD
- IMAB 0.07
- ETON 0.04
- Stochastic Oscillator
- IMAB 89.30
- ETON 70.50
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.